Loading...
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene. Imatinib inhibits the tyrosine kinase activity of the BCR-ABL protein and is an effective, frontline therapy for chronic-phase CML. However, accelera...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group
2006
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2361347/ https://ncbi.nlm.nih.gov/pubmed/16721371 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603170 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|